Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Uroplasty, Inc.
Medtech Insight recorded 17 merger or acquisition deals in March, a rise from the nine deals recorded last month and in the same period last year. It was a busy month for Boston Scientific, which racked up two acquisitions, paying $460m for urology device maker NxThera and an undisclosed price for endoscopy firm EMcision.
The deal adds Cogentix' Urgent PC neuromodulation system for urinary incontinence, PrimeSight cystoscopy system, and Macroplastique soft-tissue bulking agent to treat female stress urinary incontinence to Laborie's range of urology and gynecology products.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2016.
Cogentix Medical appoints permanent president and CEO following proxy fight; TeraRecon announces CEO and new executives; Millar Names CEO; Novadaq founder tapped as CEO; and other recent executive moves in the medtech space.
- Diagnostic Imaging Equipment & Supplies
- Implantable Devices
- Infection Control-Sterilization
- Rehabilitation Equipment and Devices
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.